OncoMatch/Clinical Trials/NCT06841055
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Is NCT06841055 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pumitamig and Docetaxel for non-small cell lung cancer.
Treatment: Pumitamig · Docetaxel — This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the combination of pumitamig (also known as BNT327, BMS-986545 or PM8002) with standard of care. Part 1 is a safety run-in with pumitamig (Dose 1 or Dose 2) plus docetaxel and will include up to 12 participants in total to be treated in Part 1A and 1B sequentially. Part 2 is a dose expansion at the deemed safe dose of pumitamig plus docetaxel and will include up to 54 participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) historical PD-L1 results must be available
Historical PD-L1 results must be available.
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — first-line advanced/metastatic
programmed death-1 [PD-1]/ programmed death ligand-1 [PD-L1] inhibitor and platinum-based chemotherapy concomitantly
Must have received: platinum-based chemotherapy — first-line advanced/metastatic
programmed death-1 [PD-1]/ programmed death ligand-1 [PD-L1] inhibitor and platinum-based chemotherapy concomitantly
Cannot have received: anti-VEGF monoclonal antibody
prior treatment with anti-vascular endothelial growth factor (VEGF) monoclonal antibody
Cannot have received: anti-PD-(L)-1/aVEGF bispecific antibody
anti-PD-(L)-1/aVEGF bispecific antibody
Cannot have received: docetaxel
docetaxel as monotherapy or in combination with other agents
Lab requirements
Blood counts
Adequate organ function as defined in the protocol.
Kidney function
Adequate organ function as defined in the protocol.
Liver function
Adequate organ function as defined in the protocol.
Adequate organ function as defined in the protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Alabama at Birmingham Hospital · Birmingham, Alabama
- Moffitt Cancer Center · Tampa, Florida
- Baptist Health Hardin · Elizabethtown, Kentucky
- NYU Langone - NYU Grossman School of Medicine · New York, New York
- Texas Oncology, P.A. · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify